Study Summary
This trial tests safety and effectiveness of a drug combo to treat advanced non-squamous lung cancer with or without STK11 mutations.
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
3 Primary · 14 Secondary · Reporting Duration: Up to 2 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
7 Treatment Groups
Phase 1b Cohort 3: Bemcentinib Dose 3
1 of 7
Phase 1b Cohort 1: Bemcentinib Dose 1
1 of 7
Phase 1b Cohort 2: Bemcentinib Dose 2
1 of 7
Phase 1b Cohort 2: Bemcentinib 100 mg
1 of 7
Phase 1b Cohort 3: Bemcentinib 150 mg
1 of 7
Phase 2a Expansion Cohort: Bemcentinib (at 2 doses as determined from Phase 1b)
1 of 7
Phase 1b Cohort 1: Bemcentinib 75 mg
1 of 7
Experimental Treatment
64 Total Participants · 7 Treatment Groups
Primary Treatment: Phase 1b Cohort 3: Bemcentinib Dose 3 · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there still vacancies in this clinical trial?
"Affirmative. According to clinicaltrials.gov, this trial is currently seeking enrolment of 64 participants from a single site. The initial posting date was December 14th 2022 and the data were last updated on April 18th 2023." - Anonymous Online Contributor
What is the current enrollment limit for this investigation?
"Affirmative. Data on clinicaltrials.gov indicates that the current recruitment of participants for this medical study commenced in December 14th, 2022 and was most recently updated April 18th, 2023. The trial is seeking to recruit 64 individuals from one site." - Anonymous Online Contributor
What aim is this medical experiment attempting to accomplish?
"The principal aim of this clinical trial, lasting for approximately 12 months, is to measure the Objective Response Rate (ORR) at 6 Months. Secondary goals include assessing Disease Control Rates (DCR), Area Under the Curve Within a Dosing Interval (AUC[0-t]), and Apparent Terminal Half-life (t1/2)." - Anonymous Online Contributor